BRPI0809143A2 - polimorfismos genéticos associados com eventos coronários e resposta a fármaco, métodos de detecção e usos dos mesmos - Google Patents

polimorfismos genéticos associados com eventos coronários e resposta a fármaco, métodos de detecção e usos dos mesmos

Info

Publication number
BRPI0809143A2
BRPI0809143A2 BRPI0809143A BRPI0809143A BRPI0809143A2 BR PI0809143 A2 BRPI0809143 A2 BR PI0809143A2 BR PI0809143 A BRPI0809143 A BR PI0809143A BR PI0809143 A BRPI0809143 A BR PI0809143A BR PI0809143 A2 BRPI0809143 A2 BR PI0809143A2
Authority
BR
Brazil
Prior art keywords
detection methods
drug response
genetic polymorphisms
polymorphisms associated
coronary events
Prior art date
Application number
BRPI0809143A
Other languages
English (en)
Inventor
Carmen Tong
Charles Rowland
James Devlin
Olga Iakoubova
Original Assignee
Celera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celera Corp filed Critical Celera Corp
Publication of BRPI0809143A2 publication Critical patent/BRPI0809143A2/pt
Publication of BRPI0809143B1 publication Critical patent/BRPI0809143B1/pt
Publication of BRPI0809143B8 publication Critical patent/BRPI0809143B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/324Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/329Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0809143A 2007-03-22 2008-03-24 método in vitro para identificar um indivíduo que apresente um risco alterado para desenvolver doença cardíaca coronária (chd) ou aneurisma/dissecção BRPI0809143B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91988507P 2007-03-22 2007-03-22
US60/919,885 2007-03-22
PCT/US2008/003857 WO2008118415A2 (en) 2007-03-22 2008-03-24 Genetic polymorphisms associated with coronary events and drug response

Publications (3)

Publication Number Publication Date
BRPI0809143A2 true BRPI0809143A2 (pt) 2016-11-16
BRPI0809143B1 BRPI0809143B1 (pt) 2020-12-01
BRPI0809143B8 BRPI0809143B8 (pt) 2021-07-27

Family

ID=39789193

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809143A BRPI0809143B8 (pt) 2007-03-22 2008-03-24 método in vitro para identificar um indivíduo que apresente um risco alterado para desenvolver doença cardíaca coronária (chd) ou aneurisma/dissecção

Country Status (6)

Country Link
US (7) US7695916B2 (pt)
EP (2) EP2592157B1 (pt)
JP (2) JP5697339B2 (pt)
BR (1) BRPI0809143B8 (pt)
CA (1) CA2680024C (pt)
WO (1) WO2008118415A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US7695916B2 (en) * 2007-03-22 2010-04-13 Celera Corporation Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof
WO2010081764A2 (de) * 2009-01-16 2010-07-22 Siemens Aktiengesellschaft Genomweite analyse zur endothelialen dysfunktion
EA201270020A1 (ru) * 2009-06-15 2012-07-30 Кардиодкс, Инк. Определение риска развития атеросклеротической болезни сердца
CN106929568A (zh) * 2009-10-07 2017-07-07 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控狼疮的方法
RU2707959C2 (ru) * 2015-01-27 2019-12-03 Астразенека Аб Способ лечения или профилактики атеротромботических явлений у пациентов с инфарктом миокарда в анамнезе
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
US20230203584A1 (en) * 2020-05-08 2023-06-29 The General Hospital Corporation Methods of predicting aneurysms of the ascending and descending aorta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510341A (ja) * 2002-02-27 2006-03-30 バイエル・ヘルスケア・アクチェンゲゼルシャフト 有害薬剤反応および薬剤効力を予測する単一ヌクレオチド多型
AU2003245488A1 (en) * 2002-06-13 2003-12-31 Regulome Corporation Functional sites
EP2186913B1 (en) * 2003-11-26 2016-02-10 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US20070059710A1 (en) * 2004-02-27 2007-03-15 Applera Corporation Genetic polymorphisms associated with stroke, methods of detection and uses thereof
US7799530B2 (en) * 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US7695916B2 (en) * 2007-03-22 2010-04-13 Celera Corporation Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof

Also Published As

Publication number Publication date
EP2140024A4 (en) 2010-06-09
JP5697339B2 (ja) 2015-04-08
EP2140024B1 (en) 2012-12-19
JP2010521969A (ja) 2010-07-01
CA2680024A1 (en) 2008-10-02
EP2592157B1 (en) 2017-08-16
US20140072550A1 (en) 2014-03-13
EP2592157A1 (en) 2013-05-15
WO2008118415A2 (en) 2008-10-02
US20170022563A1 (en) 2017-01-26
BRPI0809143B8 (pt) 2021-07-27
EP2140024A2 (en) 2010-01-06
US20080241846A1 (en) 2008-10-02
WO2008118415A3 (en) 2008-12-11
BRPI0809143B1 (pt) 2020-12-01
US10988809B2 (en) 2021-04-27
US7695916B2 (en) 2010-04-13
US20220154277A1 (en) 2022-05-19
US8148070B2 (en) 2012-04-03
JP2013138686A (ja) 2013-07-18
CA2680024C (en) 2017-07-04
US20130058914A1 (en) 2013-03-07
US11814684B2 (en) 2023-11-14
US10435749B2 (en) 2019-10-08
US20100120040A1 (en) 2010-05-13
US20200123610A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
BRPI0809143A2 (pt) polimorfismos genéticos associados com eventos coronários e resposta a fármaco, métodos de detecção e usos dos mesmos
ATE434433T1 (de) Arzneimittelabgabesystem auf basis von polyethylen-vinylacetat-copolymeren
EP1937454A4 (en) PROTECTIVE FOILS, ARTICLES AND METHODS
EP3323405C0 (en) SYSTEM AND METHOD FOR DISPENSING MEDICATION
EP1992348A4 (en) PHARMACEUTICAL COMBINATION
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
EP1968612A4 (en) NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS
BRPI0814599A2 (pt) Pesticidas e usos dos mesmos
FR2924526B1 (fr) Barre de support, nappe de barres de support et assemblage de barres de support
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
EP2193248A4 (en) SERVER RACK BLADE AND SYSTEM
BRPI0915142A2 (pt) polipeptídeos, ácido nucleico e usos dos mesmos
BRPI0808928A2 (pt) Artigos revestidos com baixae e processos de fabricação dos mesmos
BRPI0812335A2 (pt) Polimorfismos de milho e métodos de genotipagem.
DK3372281T3 (da) Polycyklisk carbamoylpyridon-derivat med HIV-integrase-hæmmende aktivitet
EP2343284A4 (en) URACIL COMPOUNDS AND HERBICIDES COMPRISING THE SAME
BRPI0821310A2 (pt) Conjugados polipeptídeos-ácido nucleico e usos dos mesmos
EP2010125A4 (en) DOSE COUNTER
BRPI0718182A2 (pt) Oligorribonucleotídeos e seus usos.
DK2298901T3 (da) Nye herbicidresistensgener
BRPI0715342A2 (pt) Derivados de 6-carboxi-normorfinano, síntese e usos dos mesmos
EP1982978A4 (en) PYRIDONE DERIVATIVES AND HERBICIDES
ATE406859T1 (de) Kanüleninfusionssystem
ATE542815T1 (de) Kokristalle und pharmazeutische zusammensetzungen damit
DK1775298T3 (da) Thienopyrazolderivat med PDE7-inhibitorisk aktivitet

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO